10.19.10
Results of a double-blind, placebo-controlled, U.S.-based clinical trial showed that proprietary humic acid from Laub BioChemicals Corporation improved flu-related symptoms, cytokine response, the immune system modulator T-cells CD4+ and CD8+ and Visual Analogue Scale (VAS) scores when study subjects were provided six 250 mg tablets daily for 14 days.
The primary objective of the 37-person clinical trial managed by KGK Synergize and conducted at two research locations in Florida, was to assess the efficacy of humic acid on flu as gauged by the alleviation of symptoms after seven and 14 days of treatment in adults with influenza A or B.
Conducted during the spring 2010 flu season, the trial found that subjects treated with humic acid showed a 107% improvement in their flu-related symptom scores. The placebo group showed a 76% improvement in VAS scores by the second week of the trial. For further information: www.laubbiochem.com
The primary objective of the 37-person clinical trial managed by KGK Synergize and conducted at two research locations in Florida, was to assess the efficacy of humic acid on flu as gauged by the alleviation of symptoms after seven and 14 days of treatment in adults with influenza A or B.
Conducted during the spring 2010 flu season, the trial found that subjects treated with humic acid showed a 107% improvement in their flu-related symptom scores. The placebo group showed a 76% improvement in VAS scores by the second week of the trial. For further information: www.laubbiochem.com
